Article info

Download PDFPDF

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Authors

  1. Correspondence to Dr Tomás Palanques-Pastor, Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia 46026, Spain; palanques_tom{at}gva.es
View Full Text

Citation

Palanques-Pastor T, López-Briz E, Poveda Andrés JL
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Publication history

  • Received April 21, 2020
  • Revised May 9, 2020
  • Accepted May 12, 2020
  • First published June 4, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.